Should Eligible Patients With T-Cell Lymphoma Receive High-Dose Therapy and Autologous Stem Cell Transplant in the Upfront Setting?
Current Oncology Reports - United States
doi 10.1007/s11912-010-0125-0
Full Text
Open PDFAbstract
Available in full text
Categories
Date
August 25, 2010
Authors
Publisher
Springer Science and Business Media LLC